NASDAQ : CAMP
Camp4 Therapeutics Corporation — Key statistics
Healthcare · Biotechnology · United States
Last price 3.9 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 244.74M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 248.50M |
| Enterprise Value | 164.48M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 62.75M |
| Shares Outstanding | 62.75M |
| Shares Change (YoY) | +239.08% |
| Shares Change (QoQ) | +0.01% |
| Owned by Insiders (%) | 1.19% |
| Owned by Institutions (%) | 53.40% |
| Float | 43.33M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 58.94 |
| Forward PS | 32.18 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 39.01 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 4.70 |
| Quick Ratio | 4.52 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -545.85% |
| Return on Assets (ROA) | -45.25% |
| Return on Invested Capital (ROIC) | -133.94% |
| Return on Capital Employed (ROCE) | -70.52% |
| Weighted Average Cost of Capital (WACC) | 5.64% |
| Revenue Per Employee | $87,833 |
| Profits Per Employee | -$2.23M |
| Employee Count | 48 |
| Asset Turnover | 0.06 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.26 |
| 52-Week Price Change | +2.59% |
| 50-Day Moving Average | 3.89 |
| 200-Day Moving Average | 4.22 |
| Relative Strength Index (RSI) | 58.91 |
| Average Volume (20 Days) | 200,346 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 3.45M |
| Short Previous Month | 1.46M |
| Short % of Shares Out | 5.50% |
| Short % of Float | 7.96% |
| Short Ratio (days to cover) | 11.12 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 4.22M |
| Gross Profit | -34.47M |
| Operating Income | -52.38M |
| Pretax Income | -107.24M |
| Net Income | -107.24M |
| EBITDA | -50.56M |
| EBIT | -52.38M |
| Loss Per Share | -$2.18 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 86.40M |
| Total Debt | 2.37M |
| Net Cash | 84.03M |
| Net Cash Per Share | $1.34 |
| Equity (Book Value) | -693,000 |
| Book Value Per Share | -0.01 |
| Working Capital | 70.89M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -28.59M |
| Capital Expenditures | -129,000 |
| Depreciation & Amortization | 1.82M |
| Net Borrowing | -129,000 |
| Free Cash Flow | -28.72M |
| FCF Per Share | -$0.46 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | -1,242.50% |
| Pretax Margin | -2,543.74% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -239.08% |
| Shareholder Yield | -239.08% |
| Earnings Yield | -54.97% |
| FCF Yield | -11.56% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $10.22 |
| Price Target Difference | 158.08% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 10 |
| Revenue Growth Forecast (3Y) | -27.57% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -4.9 |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |